Substituted phenyl phenol leukotriene antagonists
CA 2083639 C · Owner: Eli Lilly And Company · Inventors: Sofia, Michael J.; Sawyer, Jason S.; Schmittling, Elisabeth A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Antagonists having a substituted phenyl phenol or a substituted phenolic biphenyl structure and various, derivatives thereof, are specific leukotriene antagonists. Their structures use and synthesis are disclosed. Also, pharmaceutical formulations are disclosed for use in applications treating diseases or conditions characterized by excessive release of leukotriene B4 one of the, metabolites of arachidonic acid. The primary LTB4 antagonistic structures are represented as:, (see formula I), or a pharmaceutically acceptable base addition salt thereof, wherein R1, R2, R3, R4, X, Y, Z and A are described in, detail in this application.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 24, 1992 and granted November 21, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 24, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 24, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.